Design, Synthesis, and Evaluation of Neomycin-Imidazole Conjugates for RNA Cleavage

Chempluschem. 2022 Nov;87(11):e202200250. doi: 10.1002/cplu.202200250. Epub 2022 Sep 23.

Abstract

Targeting RNA with synthetic small molecules attracted much interest during recent years as a particularly promising therapeutic approach in a large number of pathologies spanning from genetic disorders, cancers as well as bacterial and viral infections. In this work, we took advantage of a known RNA binder, neomycin, to prepare neomycin-imidazole conjugates mimicking the active site of ribonuclease enzymes able to induce a site-specific cleavage of HIV-1 TAR RNA in physiological conditions. These new conjugates were prepared using a straightforward synthetic methodology and were studied for their ability to bind the target, inhibit Tat/TAR interaction and induce selective cleavage using fluorescence-based assays and molecular docking. We found compounds with nanomolar affinity, promising cleavage activity and the ability to inhibit Tat/TAR interaction with submicromolar IC50 s.

Keywords: Inhibition; RNA cleavage; RNA targeting; medicinal chemistry; neomycin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • HIV Long Terminal Repeat*
  • Imidazoles
  • Molecular Docking Simulation
  • Neomycin* / chemistry
  • Neomycin* / metabolism
  • Neomycin* / pharmacology
  • RNA Cleavage
  • RNA, Viral / chemistry
  • RNA, Viral / metabolism

Substances

  • Neomycin
  • RNA, Viral
  • Imidazoles